NCT03581591View on ClinicalTrials.gov

Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions

HypophosphatemiaHypophosphatemic RicketsPain, Chronic

Interventions

BIOLOGICAL

Burosumab

recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)

Trial Locations (1)

84015

The Focus Center, PC, Clinton

All Listed Sponsors

collaborator

Ultragenyx Pharmaceutical Inc

INDUSTRY

lead

Redwood Dermatology Sciences

OTHER

NCT03581591 - Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets | Biotech Hunter | Biotech Hunter